For a patient 4 months post‑benign right axillary lymph node biopsy who is overdue for the 3‑month follow‑up ultrasound and also due for her annual screening mammogram, what orders, ICD‑10‑CM diagnosis codes, and CPT procedure codes should be used to schedule the right axillary ultrasound and the screening mammogram?

Ordering and Coding for Overdue Axillary Ultrasound and Screening Mammogram

Schedule the right axillary ultrasound immediately using ICD-10 code R59.0 (localized enlarged lymph nodes) and proceed with the annual screening mammogram using Z12.31 (encounter for screening mammography for malignant neoplasm of breast), recognizing these are distinct clinical indications requiring separate orders.

Diagnostic Coding Strategy

Right Axillary Ultrasound (Overdue Follow-up)

• Use ICD-10 code R59.0 (localized enlarged lymph nodes, site unspecified) as the primary diagnosis for ordering the targeted right axillary ultrasound 1
• This code appropriately reflects the clinical indication: surveillance of a previously biopsied lymph node with focal cortical thickening that requires interval assessment
• Ultrasound is the recommended first-line imaging modality for evaluating axillary lymphadenopathy, providing real-time assessment of node size, morphology, and vascularity without radiation exposure 1
• The 4-month interval (1 month overdue from the 3-month recommendation) is clinically appropriate given the benign biopsy results, though timely completion is important

Screening Mammogram (Annual Surveillance)

• Use ICD-10 code Z12.31 (encounter for screening mammography for malignant neoplasm of breast) for the routine annual screening mammogram
• This is appropriate given the patient has BI-RADS 3 findings (questionable focal asymmetry and 3 mm cyst) that require continued annual surveillance 2
• Do not conflate the axillary lymph node surveillance with breast cancer screening—these are separate clinical pathways with distinct indications

Procedural Coding

Right Axillary Ultrasound

• CPT 76882 (ultrasound, limited, anatomic structure) or CPT 76604 (ultrasound, chest [includes mediastinum], real-time with image documentation) may be appropriate depending on institutional coding practices
• The order should specify "right axillary ultrasound" with indication of "follow-up of benign lymph node with cortical thickening"

Screening Mammogram

• CPT 77067 (screening mammography, bilateral, including computer-aided detection when performed)
• Consider digital breast tomosynthesis (DBT) if available, as it increases cancer detection rates and decreases false-positive recalls, particularly beneficial for asymmetries like those present in this patient 2

Clinical Rationale for Separate Orders

These must be two distinct orders because they address different anatomic sites and clinical questions:

• The axillary ultrasound is diagnostic surveillance of a known abnormality (benign lymph node with cortical thickening) requiring interval stability assessment 1, 3
• The screening mammogram is routine breast cancer screening for BI-RADS 3 findings that warrant annual follow-up 2
• Sonographic evaluation of isolated axillary lymph nodes identified on prior imaging helps improve specificity and characterize nodes that may harbor occult pathology 3, 4

Follow-up Surveillance Framework

After benign breast biopsy, increased surveillance is necessary:

• Imaging (mammography or ultrasound) and clinical breast examination at 6 months, 1 year, and 2 years post-biopsy is supported by evidence showing 13% of patients require subsequent biopsy and 1.9% develop cancer within 2 years 5
• This patient's BI-RADS 3 breast findings (focal asymmetry and cyst) require annual mammographic surveillance 2
• The axillary lymph node requires separate ultrasound follow-up given the focal cortical thickening, even though biopsy was benign 1, 3

Common Pitfalls to Avoid

• Do not use a breast-related diagnosis code (such as N63.11 for breast mass) for the axillary ultrasound order—this misrepresents the clinical indication and may result in claim denial
• Do not delay the overdue axillary ultrasound waiting to coordinate it with the mammogram—these serve different purposes and the axillary study is already overdue
• Do not assume normal axillary imaging excludes pathology—ultrasound and mammography combined have a negative predictive value of only 82.8% for axillary metastasis, though this patient's benign biopsy significantly reduces concern 6
• Ensure the patient understands these are separate studies addressing different clinical concerns to improve compliance with both examinations